QCIG
PLX icon

Quad-Cities Investment Group’s Protalix BioTherapeutics PLX Stock Holding History

Quad-Cities Investment Group’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-50
Closed – – 856
2019
Q1 		$0 Hold
50
– – ﹤0.01% 873
2018
Q4 		$0 Hold
50
– – ﹤0.01% 871
2018
Q3 		$0 Hold
50
– – ﹤0.01% 856
2018
Q2 		$0 Buy
+50
New +$222 ﹤0.01% 850

Other funds holding PLX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Quad-Cities Investment Group's PLX Position: Q2 2019 in Review

Quad-Cities Investment Group sold out of Protalix BioTherapeutics (PLX) in Q2 2019, closing a stake of 50 shares.

Quad-Cities Investment Group first reported a position in PLX in Q2 2018 and held it in 4 quarters. The position peaked at $0 in Q1 2019. 31 funds tracked by Wall St. Rank hold PLX as of Q2 2019.

  • Quad-Cities Investment Group reported no remaining Protalix BioTherapeutics position as of Q2 2019 after selling out during the quarter.
  • Quad-Cities Investment Group sold 50 Protalix BioTherapeutics shares in Q2 2019.
  • Quad-Cities Investment Group first reported a position in Protalix BioTherapeutics in Q2 2018 and held it in 4 quarters.
  • Quad-Cities Investment Group's Protalix BioTherapeutics position peaked at $0 in Q1 2019.
  • 31 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2019.

Based on Quad-Cities Investment Group's 13F filing for Q2 2019, filed 17 Jul 2019.